The DOI matches its Crossref record.
Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species
Open accessAbstract
Abstract: Oxidation of l ‐3,4‐dihydroxyphenylalanine ( l ‐DOPA) and dopamine (DA) to generate semiquinones/quinones, oxygen radicals, and other reactive oxygen species may play a role in neuronal cell death in Parkinson's disease (PD). In particular, semiquinones/quinones can form conjugates with thiol compounds such as GSH and cysteine. Exposure of l ‐DOPA, DA, and other catecholamines to a system generating O 2 •− radical led to O 2 •− ‐dependent depletion of added GSH (or cysteine), accompanied by the formation of thiol‐DA or ‐DOPA adducts as detected by HPLC. Superoxide could additionally cause destruction of these adducts. Iron or copper ions could also promote conjugate formation between GSH or cysteine and DA and l ‐DOPA, especially if H 2 O 2 was present. We applied HPLC to measure glutathionyl and cysteinyl conjugates of l ‐DOPA, DA, and 3,4‐dihydroxyphenylacetic acid (DOPAC) in postmortem brain samples from PD patients and normal control subjects. Conjugates were detected in most brain areas examined, but levels were highest in the substantia nigra and putamen. In most regions, adduct levels were lower in PD, but there were significant increases in cysteinyl adducts of l ‐DOPA, DA, and DOPAC in PD substantia nigra, suggesting that acceleration of l ‐DOPA/DA oxidation occurs in PD, although we cannot say if this is a primary feature of the disease or if it is related to therapy with l ‐DOPA. In vitro, conjugate formation could be inhibited by the dithiol dihydrolipoate but not by its oxidised form, lipoic acid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Observation of cysteinyl adducts of dopamine in substantia nigra postmortem samples confirmed severe oxidation process occurring in PD brain. (Spencer et al. 1998).”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Spencer et al. 1998
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 1
- Halliwell B. and Gutteridge J. M. C. (1989) Free Radicals in Biol- ogy and Medicine, 2nd edit. Clarendon Press, Oxford.
Cited by
Sorted by citations
Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release
Zorov, D. B., Juhaszova, M., & Sollott, S. J. (2014) · Physiological Reviews · doi:10.1152/physrev.00026.2013 · Cited by 5,383
“In addition, PD is hallmarked by elevated iron levels that may catalyze production of deadly oxidants, possibly in a self-amplifying mode (411).”
BackgroundOxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
Self-citationReactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Self-citationOxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
“[62].”
Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
“[133] The striatum has been estimated to have an ‘average’ dopamine”
BackgroundSelf-citationGlutathione, oxidative stress and neurodegeneration
Schulz, J. B., Lindenau, J. H., Seyfried, J., & DICHGANS, J. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01595.x · Cited by 1,225
“If cysteine is not used for the synthesis of glutathione, it may react with the dopamine-o-quinone, which results from nonenzymatic oxidation of dopamine, to form 5-S-cysteinyldopamine [39].”
BackgroundGlutathione dysregulation and the etiology and progression of human diseases
Ballatori, N., Krance, S. M., Notenboom, S., Shi, S., Tieu, K., & Hammond, C. L. (2009) · Biological Chemistry · doi:10.1515/bc.2009.033 · Cited by 1,145
“…dopamine causes the depletion of GSH, and indeed, intrastriatal injection of dopamine causes a significant decrease in GSH levels (Rabinovic and Hastings, 1998), probably through the interactions of dopamine quinone with GSH and/or cysteine (Spencer et al., 1998; Hirrlinger et al., 2002b ).”
BackgroundOxidative stress and Parkinson’s disease
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878
Role of Oxidative Stress in Parkinson's Disease
Hwang, O. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.11 · Cited by 861
“Higher levels of cysteinyl-catechol derivatives are found in postmortem nigral tissues of PD patients compared to agematched controls, suggesting cytotoxic nature of DA oxidation [22].”
BackgroundDopamine covalently modifies and functionally inactivates parkin
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722
“, and are found in cerebrospinal fluid of individuals with Parkinson diseas”
BackgroundBerman, S. B., & Hastings, T. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731127.x · Cited by 664
Glutathione Pathways in the Brain
Dringen, R., & Hirrlinger, J. (2003) · Biological Chemistry · doi:10.1515/bc.2003.059 · Cited by 597
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 587
“enhanced oxidative stress in the brains of PD patients includes increased oxidation of lipids, DNA and proteins and has been documented in a large number of studies (Owen et al., 1996; Spencer et al., 1998; Halliwell, 2006; Waragai et al., 2006).”
BackgroundThe neuroprotective potential of flavonoids: a multiplicity of effects
Vauzour, D., Vafeiadou, K., Rodriguez‐Mateos, A., Rendeiro, C., & Spencer, J. P. E. (2008) · Genes & Nutrition · doi:10.1007/s12263-008-0091-4 · Cited by 561
“The death of nigral neurons in Parkinson’s disease is thought to involve the formation of the endogenous neurotoxin, 5-S-cysteinyl-dopamine [108, 109].”
BackgroundSelf-citationThe chemistry and biology of nitroxide compounds
Soule, B. P., Hyodo, F., Matsumoto, K.-I., Simone, N. L., Cook, J. A., Krishna, M. C., & Mitchell, J. B. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.02.030 · Cited by 520
“ROS formation and the oxidation of dopamine are thought to contribute to this process [80–84].”
BackgroundAsanuma, M., Miyazaki, I., & Ogawa, N. (2003) · Neurotoxicity Research · doi:10.1007/bf03033137 · Cited by 518
“…acid concentration ratio was significantly higher in cerebrospinal fluid (Cheng te al., 1996), while 5-cysteinyl-catechol conjugates (5-cysteinyl-DA, 5-cysteinyl-DOPA, and 5-cysteinyl-DOPAC) were significantly increased in the SN compared with controls (Spencer et al., 1998).”
ResultMitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
Hauser, D. N., & Hastings, T. G. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.011 · Cited by 487
Jicha, G. A., Berenfeld, B., & Davies, P. J. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990315)55:6 · Cited by 119
Williams, R. J., & Spencer, J. P. E. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.09.010 · Cited by 448
Praet, J., Guglielmetti, C., Berneman, Z., Van der Linden, A., & Ponsaerts, P. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.10.004 · Cited by 435
Toxicity of amphetamines: an update
Carvalho, M. C., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., Remião, F., Carvalho, F. D., & Bastos, M. D. L. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0815-5 · Cited by 449
“These metabolites, formed in liver cells, can reach the heart, the kidney, the brain, and other organs via the circulation and produce their toxic effects, mainly due to the auto-oxidation of the catecholic groups into reactive o-quinones (Macedo et al. 2007; Spencer et al. 1998).”
BackgroundZecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401
Conducting polymer-based electrochemical biosensors for neurotransmitters: A review
Moon, J., Thapliyal, N. B., Hussain, K. K., Goyal, R. N., & Shim, Y. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.11.069 · Cited by 390
Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K. M., Laurie, C. D., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 393
“Other possibilities of mechanisms for diminished levels include increased removal of GSH from cells by γ-glutamyltranspeptidase [109] and the formation of adducts of glutamyl and cysteinyl peptides of GSH with dopamine [114-116].”
BackgroundAutophagy as an essential cellular antioxidant pathway in neurodegenerative disease
Giordano, S. S., Darley-Usmar, V. M., & Zhang, J. (2013) · Redox Biology · doi:10.1016/j.redox.2013.12.013 · Cited by 372
Parkinsonian Mimetics Induce Aspects of Unfolded Protein Response in Death of Dopaminergic Neurons
Holtz, W. A., & O’Malley, K. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211821200 · Cited by 368
The impact of fruit flavonoids on memory and cognition
Spencer, J. P. E. (2010) · British Journal Of Nutrition · doi:10.1017/s0007114510003934 · Cited by 369
“S -cysteinyl-dopamine and its oxidation product, dihydrobenzothiazine-1 (5,85–87) .”
Self-citationLipoic acid - the drug of the future?
Bilska‐Wilkosz, A., & Włodek, L. B. (2005) · PubMed · Cited by 349
Flavonoids and brain health: multiple effects underpinned by common mechanisms
Spencer, J. P. E. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0136-3 · Cited by 330
“Such adducts may be generated by reactive species [73] and have been observed to be elevated in the human substantia nigra of patients who died of Parkinson’s disease [62], suggesting that such species may be potential endogenous nigral toxins.”
BackgroundSelf-citationSpencer, J. P. E., Mohsen, M. M. A. E., & Rice-Evans, C. A. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.11.010 · Cited by 329
Self-citationMercury Toxicity and Neurodegenerative Effects
Carocci, A., Rovito, N., Sinicropi, M. S., & Genchi, G. (2013) · Reviews of Environmental Contamination and Toxicology · doi:10.1007/978-3-319-03777-6_1 · Cited by 334
“In conclusion, depletion of GSH, breakage of mitochondria, increased lipid peroxidation, and oxidation of proteins and DNA in the brain, induced by mercury and his salts, appear to be important factors in conditions such as ALS and AD (Bains and Shaw 1997; Nicole et al. 1998; Spencer et al. 1998; Alberti et al. 1999).”
BackgroundAutoxidation and Neurotoxicity of 6‐Hydroxydopamine in the Presence of Some Antioxidants
Soto‐Otero, R., Méndez‐Álvarez, E., Ameijeiras, Á. H., Muñoz, A., & Labandeira-García, J. L. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741605.x · Cited by 314
RETRACTED: Glycogen synthase kinase 3β (GSK3β) mediates 6‐ hydroxydopamine‐induced neuronal death
Chen, G., Bower, K. A., Ma, C., Fang, S., Thiele, C. J., & Luo, J. (2004) · The FASEB Journal · doi:10.1096/fj.04-1551fje · Cited by 311
RetractedRole of dopamine in the pathophysiology of Parkinson’s disease
Zhou, Z., Yi, L., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00378-6 · Cited by 356
Redox imbalance in Parkinson's disease
Chinta, S. J., & Andersen, J. K. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.02.005 · Cited by 303
“Along with decreased GSH levels, elevated levels of 5-S-cysteinyl-catecholamine conjugates such as 5-S-cys DA, 5-S- cysDOPAC have also been reported in the SN of individuals with PD [44].”
BackgroundGeorgiou‐Siafis, S. K., & Tsiftsoglou, A. S. (2023) · Antioxidants · doi:10.3390/antiox12111953 · Cited by 334
“In this case, when the cysteinyl-S adduct contains a strong electron-withdrawing structure, cysteine S-conjugate β -lyases convert it to another chemical compound, comprising the sulfhydryl group attached to the parent electrophile, pyruvate, and ammonium.”
BackgroundMolecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Capela, J. P., Carmo, H., Remião, F., Bastos, M. D. L., Meisel, A., & Carvalho, F. D. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8064-1 · Cited by 294
Calabrese, V., Bates, T. E., & Stella, A. M. G. (2000) · Neurochemical Research · doi:10.1023/a:1007604414773 · Cited by 285
“Decreased glutathione peroxidase and catalase activities associated with increased SOD activity leads to increased levels of hydrogen peroxide (214).”
Sulforaphane as a Potential Protective Phytochemical against Neurodegenerative Diseases
Tarozzi, A., Angeloni, C., Malaguti, M., Morroni, F., Hrelia, S., & Hrelia, P. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/415078 · Cited by 296
“CysDA adducts have been reported in human brain tissue and are elevated in the brains of patients suffering from PD [114].”
BackgroundNutrition, Brain Aging, and Neurodegeneration: Table 1.
Joseph, J., Cole, G., Head, E., & Ingram, D. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3520-09.2009 · Cited by 264
“…to contribute to the increased vulnerability to oxidative stress seen in the aging population (Halliwell, 2001; Rego and Oliveira, 2003) and which is elevated in AD (Smith et al., 1991; Lovell et al., 1995; Marcus et al., 1998) and Parkinson disease (PD) (Dexter et al., 1994; Spencer et al., 1998).”
BackgroundDrug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 275
“The resultant semiquinones/ quinones can also form conjugates with thiol compounds such as GSH and cysteine (Spencer et al., 1998).”
BackgroundOxidative damage in Parkinson disease: Measurement using accurate biomarkers
Seet, R. C. S., Lee, J. C., Lim, E. C. H., Tan, J. J. H., Quek, A. M. L., Chong, W.-L., Looi, W. F., Huang, S.-H., Wang, H., Chan, Y., et al. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.026 · Cited by 255
Self-citationIntracellular metabolism and bioactivity of quercetin and its in vivo metabolites
Spencer, J. P. E., Kuhnle, G., WILLIAMS, R. J., & Rice-Evans, C. A. (2003) · Biochemical Journal · doi:10.1042/bj20021972 · Cited by 241
Self-citationCorona, G., Tzounis, X., Dessì, M., Deiana, M., Debnam, E. S., Visioli, F., & Spencer, J. P. E. (2006) · Free Radical Research · doi:10.1080/10715760500373000 · Cited by 231
“[24] for catecholamine conjugates, with some modifications.”
Self-citationFlavonoids and cognition: The molecular mechanisms underlying their behavioural effects
Spencer, J. P. E., Vauzour, D., & Rendeiro, C. (2009) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2009.10.003 · Cited by 235
Self-citationMetodiewa, D., & Kośka, C. (1999) · Neurotoxicity Research · doi:10.1007/bf03033290 · Cited by 226
The role of Coenzyme Q in mitochondrial electron transport
Lenaz, G., Fato, R., Formiggini, G., & Genova, M. L. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.009 · Cited by 230
Richardson, J. R., Caudle, W. M., Wang, M., Dean, E. D., Pennell, K. D., & Miller, G. W. (2006) · The FASEB Journal · doi:10.1096/fj.06-5864fje · Cited by 215
“in postmortem PD brains (49), and 5-cysteinyl dopa-”
BackgroundJunn, E., & Mouradian, M. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00425.x · Cited by 214
Glutathione and Parkinson's disease: Is this the elephant in the room?
Zeevalk, G. D., Razmpour, R., & Bernard, L. P. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.01.017 · Cited by 217
Oxidative and nitrative protein modifications in Parkinson's disease
Danielson, S. R., & Andersen, J. K. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.005 · Cited by 204
“catecholamine adducts have been found in the SN of PD patients and have been reported to result in inhibition of mitochondrial complex I, a hallmark of the disease [37].”
BackgroundGrape Juice, Berries, and Walnuts Affect Brain Aging and Behavior
Joseph, J. A., Shukitt‐Hale, B., & Willis, L. (2009) · Journal of Nutrition · doi:10.3945/jn.109.108266 · Cited by 203
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease
Hastings, T. G. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9257-z · Cited by 199
Macready, A. L., Kennedy, O. B., Ellis, J. A., Williams, C. M., Spencer, J. P. E., & Butler, L. T. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0135-4 · Cited by 204
“In PD, for instance, the selective and progressive loss of dopaminergic neurons in the substantia nigra may be indirectly caused by oxidation of dopamine in the presence of cellular thiols such as cysteine [64, 70].”
Self-citationMoss, D. W., & Bates, T. E. (2001) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2001.01418.x · Cited by 192
“OH) radicals (Spencer et al., 1998).”
BackgroundInfluentialKuhn, D. M., Arthur, R. E., Thomas, D. M., & Elferink, L. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731309.x · Cited by 184
Pifl, C., Rajput, A. H., Reither, H., Blesa, J., Cavada, C., Obeso, J. A., Rajput, A. H., & Hornykiewicz, O. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5456-13.2014 · Cited by 170
“, 1978), promoting formation of reactive oxygen species (Hastings et al., 1996; Spencer et al., 1998), as well as normally metabolized intracellularly by monoamine oxidase to DOPAC, with reactive molecules as intermediates.”
BackgroundThe mitochondrial free radical theory of ageing - Where do we stand?
Gruber, J. (2008) · Frontiers in bioscience · doi:10.2741/3174 · Cited by 171
“This increase in oxidative damage might partly originate from the formation of cytotoxic L-dopa-cysteinyl adducts, which are elevated in the SN of PD patients (147).”
BackgroundVauzour, D., Corona, G., & Spencer, J. P. E. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.03.016 · Cited by 166
Self-citationSun, Y., He, L., Wang, T., Wan, H., Qin, H., Wang, J., Wang, L., Gu, W., Li, T., Li, N., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02049-3 · Cited by 163
Spencer, J. P. E. (2010) · Proceedings of The Nutrition Society · doi:10.1017/s0029665110000054 · Cited by 163
“Such adducts may be generated by reactive species (130) and have been observed post mortem to be elevated in the substantia nigra of patients with Parkinson’s disease (131) , suggesting that such species may be potential endogenous nigral toxins.”
Self-citationCarvey, P. M. (2003) · Frontiers in bioscience · doi:10.2741/1158 · Cited by 161
Masoud, S. T., Vecchio, L. M., Bergeron, Y., Hossain, M. M., Nguyen, L., Bermejo, M. K., Kile, B. M., Sotnikova, T. D., Siesser, W. B., Gainetdinov, R. R., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.10.016 · Cited by 158
“Secondly, oxidative stress has long been postulated to be involved in the development of PD (Fahn and Cohen, 1992) and we report that DAT-tg mice display increased levels of cysteinyl-dopamine and cysteinyl-DOPAC, two markers that are also elevated in the SN of PD patients (Spencer et al., 1998).”
BackgroundExpression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra
Muiswinkel, F. L. V., de Vos, R. A. I., Bol, J. G. J. M., Andringa, G., Steur, E. N. H. J., Ross, D., Siegel, D. M., & Drukarch, B. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.010 · Cited by 155
“Given the depletion of GSH and the increased levels of cysteinyl conjugates of DA in the SNpc of PD patients, and the chemical composition of the neuromelanin pigment, it is evident that the DA driven prooxidative pathway is indeed operative in vivo [15, 48 ].”
BackgroundTaurine and central nervous system disorders
Menzie, J., Pan, C., Prentice, H. M., & Wu, J. (2012) · Amino Acids · doi:10.1007/s00726-012-1382-z · Cited by 153
“2005) observed in patients of Parkinson’s disease (Spencer et al. 1998).”
BackgroundHaque, M. E., Asanuma, M., Higashi, Y., Miyazaki, I., Tanaka, K.-I., & Ogawa, N. (2002) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00440-3 · Cited by 151
Suh, J. H., Wang, H., Liu, R.-M., Liu, J., & Hagen, T. M. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.12.020 · Cited by 147
Astrocytes as new targets to improve cognitive functions
Dallérac, G. M., & Rouach, N. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.003 · Cited by 155
The cytotoxicity of dopamine may be an artefact of cell culture
Clement, M., Long, L. H., Ramalingam, J. K., & Halliwell, B. B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00802.x · Cited by 140
Self-citationAndreadou, E., Nikolaou, C., Gournaras, F., Rentzos, M., Boufidou, F., Tsoutsou, A., Zournas, C., Zissimopoulos, V., & Vassilopoulos, D. (2009) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2009.06.012 · Cited by 137
Chakrabarti, S., & Bisaglia, M. (2023) · Antioxidants · doi:10.3390/antiox12040955 · Cited by 145
“Consistent with these results, higher levels of cysteinyl DA adducts were found in the PD substantia nigra of post-mortem brain samples in comparison to those of the control subjects, although the authors pointed out that their observation could have arisen from the L-DOPA treatment the PD patients took to alleviate t…”
ResultThe transcription factor Nrf2 as a new therapeutic target in Parkinson's disease
Cuadrado, A., Moreno-Murciano, P., & Pedraza‐Chaverrí, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/13543780802716501 · Cited by 135
“A mechanism to attenuate the cytotoxic effect of DA quinone is the sequestration with GSH to form 55(-S-glutathionyl-DA, but this involves the expense of GSH, a central molecule to keep redox homeostasis [24] .”
BackgroundKim, J., Lee, S., Shim, J., Kim, H. W., Kim, J., Jang, Y. J., Yang, H. S., Park, J., Choi, S. H., Yoon, J. H., et al. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.02.004 · Cited by 133
Therapeutic and Clinical Applications of Nitroxide Compounds
Soule, B. P., Hyodo, F., Matsumoto, K.-I., et al. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1722 · Cited by 127
“In Parkinson’s disease, dopamine oxidation and ROS formation are thought to contribute to the process of progressively worsening motor function (3, 54, 58, 85, 99).”
Holtz, W. A., Turetzky, J. M., Jong, Y.-J. I., & O’Malley, K. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04025.x · Cited by 126
Giacoppo, S., Galuppo, M., Montaut, S., Iori, R., Rollin, P., Bramanti, P., & Mazzon, E. (2015) · Fitoterapia · doi:10.1016/j.fitote.2015.08.001 · Cited by 126
“In fact, 5-S-cysteinyl-dopamine (CysDA) adducts result elevated in the brains of patients affected by PD [50].”
BackgroundCu(II)-catalyzed oxidation of dopamine in aqueous solutions: Mechanism and kinetics
Pham, A. N., & Waite, T. D. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.03.018 · Cited by 121
Prodrug Approach for Increasing Cellular Glutathione Levels
Cacciatore, I., Cornacchia, C., Pinnen, F., Mollica, A., & Stefano, A. D. (2010) · Molecules · doi:10.3390/molecules15031242 · Cited by 121
Neuroprotective Effect of Eicosapentaenoic Acid in Hippocampus of Rats Exposed to γ-Irradiation
Lonergan, P. E., Martin, D. S. D., Horrobin, D. F., & Lynch, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202387200 · Cited by 119
Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins
Double, K. L., Zecca, L., Costi, P., Mauer, M. S., Griesinger, C., Ito, S., Ben‐Shachar, D., Bringmann, G., Fariello, R. G., Riederer, P. F., et al. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752583.x · Cited by 119
Insights into Melanosomes and Melanin from Some Interesting Spatial and Temporal Properties
Simon, J. D., Hong, L., & Peles, D. N. (2008) · The Journal of Physical Chemistry B · doi:10.1021/jp804248h · Cited by 119
Why Is the Nervous System Vulnerable to Oxidative Stress?
Friedman, J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-514-9_2 · Cited by 121
“9 Autooxidation of Neurotransmitters [9–11]”
Natural isothiocyanates: Genotoxic potential versus chemoprevention
Fimognari, C., Turrini, E., Ferruzzi, L., Lenzi, M., & Hrelia, P. (2011) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2011.12.001 · Cited by 116
“Cysteinyldopamine adducts are indeed elevated in the brains of patients suffering from Parkinson disease [92].”
BackgroundKerry, N. L., & Rice-Evans, C. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730247.x · Cited by 113
Fruit Polyphenols and Their Effects on Neuronal Signaling and Behavior in Senescence
Joseph, J. A., Shukitt‐Hale, B., & Lau, F. C. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1395.052 · Cited by 114
Spencer, J. P. E., Whiteman, M., Jenner, P. G., & Halliwell, B. B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00808.x · Cited by 113
Self-citationLaar, V. S. V., Dukes, A. A., Cascio, M., & Hastings, T. G. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.11.007 · Cited by 109
Michalska, P., & Leon, R. M. (2020) · Antioxidants · doi:10.3390/antiox9080740 · Cited by 119
“DA, L-DOPA, or norepinephrine can react with O2 to generate O2•− and quinones/semiquinones that can deplete GSH and react with protein Cys residues [81].”
BackgroundRecent Advances in the Treatment of Neurodegenerative Diseases Based on GSH Delivery Systems
Cacciatore, I., Baldassarre, L., Fornasari, E., Mollica, A., & Pinnen, F. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/240146 · Cited by 106
Dopamine Biosynthesis Is Regulated byS-Glutathionylation
Borges, C. R., Geddes, T. J., Watson, J. T., & Kuhn, D. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209042200 · Cited by 102
Nutritional intervention in brain aging: reducing the effects of inflammation and oxidative stress.
Lau, F. C., Shukitt‐Hale, B., & Joseph, J. A. (2007) · PubMed · Cited by 100
Neuroproteomics: Expression Profiling of the Brain's Proteomes in Health and Disease
Kim, S. I., Voshol, H., van Oostrum, J., Hastings, T. G., Cascio, M., & Glucksman, M. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000023618.35579.7c · Cited by 104
“In PD brain, cysteinyl-DA levels are increased in substantia nigra as compared to control brains (99), suggesting that this reaction is occurring in vivo.”
BackgroundTakata, M., Yamaguchi, F., Nakanose, K., et al. (2005) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.100.511 · Cited by 99
Aspartic Acid-Promoted Highly Selective and Sensitive Colorimetric Sensing of Cysteine in Rat Brain
Qian, Q., Deng, J., Wang, D., et al. (2012) · Analytical Chemistry · doi:10.1021/ac3024608 · Cited by 98
New Insights Into Structure and Function of Mitochondria and Their Role in Aging and Disease
Lenaz, G., Baracca, A., Fato, R., Genova, M. L., & Solaini, G. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.417 · Cited by 102
Galvin, J. E. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0096-2 · Cited by 98
“, glutathione) [92] and account for pathology due to pesticide expo-”
BackgroundVauzour, D., Ravaioli, G. M., Vafeiadou, K., Rodriguez‐Mateos, A., Angeloni, C., & Spencer, J. P. E. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.011 · Cited by 96
Self-citationSynthesis and Characterization of Aminopropyltriethoxysilane-Polydopamine Coatings
Knorr, D. B., Tran, N. T., Gaskell, K. J., Orlicki, J. A., WOICIK, J. C., Jaye, C., Fischer, D. A., & Lenhart, J. L. (2016) · Langmuir · doi:10.1021/acs.langmuir.6b00531 · Cited by 100
Metadata
- Authors
- Spencer, J. P. E., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., & Halliwell, B.
- Affiliations
- University of London (GB)
- King's College London (GB)
- Parkinson's UK (GB)
- Corresponding author
- Spencer, Jeremy P. E.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 1998-11
- Volume
- 71
- Issue
- 5
- Pages
- 2112-2122
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2165866163
- Cited by
- 373
- References
- 0
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 7 · 2020: 8 · 2019: 10 · 2018: 2 · 2017: 11 · 2016: 10 · 2015: 14 · 2014: 15 · 2013: 12 · 2012: 19
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Parkinson's disease, catecholamines, L-DOPA, dopamine, glutathione conjugates, cysteine conjugates, reactive oxygen species, superoxide, semiquinone, quinones, oxidative stress, neuronal cell death, substantia nigra, putamen, alpha-lipoic acid, postmortem brain
- MeSH terms
- Aged, Aged, 80 and over, Chromatography, High Pressure Liquid, Copper, Cysteine, Dihydroxyphenylalanine, Dopamine, Glutathione, Humans, Iron, Parkinson Disease, Reference Values, Superoxides, 3,4-Dihydroxyphenylacetic Acid, 8,11,14-Eicosatrienoic Acid, Reactive Oxygen Species, Hypoxanthine, Xanthine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
